Arecor Therapeutics Past Earnings Performance
Past criteria checks 0/6
Arecor Therapeutics's earnings have been declining at an average annual rate of -32.5%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 17% per year.
Key information
-32.5%
Earnings growth rate
-17.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 17.0% |
| Return on equity | -71.3% |
| Net Margin | -278.8% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Arecor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 3 | -9 | 8 | 7 |
| 31 Mar 23 | 3 | -9 | 7 | 8 |
| 31 Dec 22 | 2 | -9 | 5 | 9 |
| 30 Sep 22 | 2 | -8 | 4 | 8 |
| 30 Jun 22 | 1 | -7 | 2 | 8 |
| 31 Mar 22 | 1 | -7 | 2 | 7 |
| 31 Dec 21 | 1 | -6 | 2 | 5 |
| 30 Sep 21 | 1 | -5 | 2 | 5 |
| 30 Jun 21 | 1 | -5 | 2 | 4 |
| 31 Mar 21 | 2 | -4 | 2 | 4 |
| 31 Dec 20 | 2 | -3 | 2 | 4 |
| 31 Dec 19 | 2 | -2 | 2 | 4 |
| 31 May 19 | 1 | -2 | 1 | 3 |
| 31 May 18 | 1 | -1 | 1 | 2 |
Quality Earnings: AREC is currently unprofitable.
Growing Profit Margin: AREC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AREC is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.
Accelerating Growth: Unable to compare AREC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AREC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: AREC has a negative Return on Equity (-71.31%), as it is currently unprofitable.